Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 20
Filtrar
1.
Thyroid ; 17(12): 1269-76, 2007 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17988196

RESUMEN

Ultrasonography is the most useful tool for detection and evaluation of thyroid nodules. In this study, we present our classification system for ultrasonographic evaluation, which has been routinely performed since 1995. Of 1244 nodules identified by ultrasonography in 900 patients, 1145 nodules demonstrating adequate specimens on fine-needle aspiration biopsy were enrolled in the study. We stratified these nodules into classes 1 to 5 with intermediate steps of 0.5 for classes 2 to 5. Nodules classified as 3.5 or greater were evaluated as malignant, those classified as 3 were evaluated as borderline, and those classified as 2.5 or lower were evaluated as benign. Of 233 nodules evaluated as malignant, 179 (76.8%) were cytologically confirmed as malignant. Furthermore, 145 of 159 nodules (91.2%) classified as 4 or greater were cytologically diagnosed as carcinoma. Of 710 nodules evaluated as benign, 683 (96.1%) were cytologically confirmed as benign. Two hundred fifty-five nodules of 210 patients were surgically resected and pathologically examined. In this series, the positive predictive value of ultrasonographic evaluation of malignancy was 97.2%. These findings suggest that our classification system is simple and useful to facilitate ultrasonographic evaluation of thyroid nodules.


Asunto(s)
Nódulo Tiroideo/clasificación , Nódulo Tiroideo/diagnóstico por imagen , Biopsia con Aguja Fina , Carcinoma Papilar/diagnóstico por imagen , Carcinoma Papilar/patología , Diagnóstico Diferencial , Humanos , Valor Predictivo de las Pruebas , Neoplasias de la Tiroides/diagnóstico por imagen , Neoplasias de la Tiroides/patología , Nódulo Tiroideo/patología , Ultrasonografía
2.
Thyroid ; 15(3): 251-8, 2005 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-15785244

RESUMEN

Recent advances permitting high-resolution ultrasonography have made ultrasonographic examination of nodular thyroid diseases an accessible examination for routine practice. However, diagnostic criteria for ultrasonographic examination of thyroid nodules are not surely established. To identify the optimal strategy for well standardized differential diagnosis of papillary thyroid carcinoma and benign nodules, we evaluated the significance of individual ultrasonographic characteristics of thyroid nodules in a multicenter study. Ten characteristics in ultrasonograms from 53 patients scored by 17 investigators from 15 centers were analyzed by t tests and logistic regression analyses. Between benign and papillary thyroid cancer groups, all characteristics but not size or multiplicity of strong echoes, which suggest calcifications, were significant parameters. Logistic regression analyses showed that border character, shape, and internal echo level are highly significant parameters (p < 0.0005). A multiple logistic regression showed to be the most important predictors of pathologic diagnosis. The diagnostic criterion with border character and internal echo level yielded 93% sensitivity and 92% specificity. In conclusion, univariate and multivariate analyses identified border character, shape, internal echo level, but not strong echoes (calcifications), as important characteristics in differentiating papillary thyroid carcinoma from benign nodules. These results will contribute to standardization of accurate ultrasonographic diagnosis of papillary thyroid carcinoma.


Asunto(s)
Adenocarcinoma Papilar/diagnóstico por imagen , Neoplasias de la Tiroides/diagnóstico por imagen , Ultrasonografía Doppler/métodos , Humanos , Estudios Retrospectivos , Sensibilidad y Especificidad , Enfermedades de la Tiroides/diagnóstico por imagen
3.
Diagnosis (Berl) ; 2(1): 53-59, 2015 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-29542308

RESUMEN

BACKGROUND: While the faecal immunochemical test for haemoglobin (FIT) is an important screening tool to detect gastrointestinal bleeding, false-negative cases resulting from the enterobacterial degradation of haemoglobin (Hb) have emerged. When faecal Hb tests have given false-negative results, it is considered that digestive bleeding diseases can be detected by measuring faecal transferrin (Tf), which is less susceptible to enterobacterial degradation. This study evaluated the benefit of measuring both Hb and Tf as markers of blood in the faeces during a large-scale colorectal cancer screening trial in Japan. METHODS: We screened 12,255 participants, i.e., 8223 men and 4032 women, for faecal Hb and Tf using a Discrete Clinical Chemistry Analyser NS-Plus C15 system. RESULTS: Among the 1232 participants with positive test results for blood, 417 were detected based solely on Tf, which increased the positive rate from 6.7% to 10.1%. The Hb and Tf concentrations were not correlated directly, thereby suggesting that Tf can detect a positive group that differs from that detected based on Hb. The positive rate for Tf alone was significantly higher in women (4.9%) compared with men (2.7%) (p<0.0001), which may be explained by the significantly higher constipation complaint rate in the Tf-positive group compared with the haemoglobin-only-positive group (p=0.0069). CONCLUSIONS: The results of this large-scale colorectal cancer screening study suggest that analysing both Hb and Tf using an NS-Plus system should be beneficial for subjects who are missed by conventional Hb testing alone.

4.
Cancer Lett ; 192(1): 83-7, 2003 Mar 20.
Artículo en Inglés | MEDLINE | ID: mdl-12637156

RESUMEN

p130 belongs to the retinoblastoma-related gene family, and its gene product works to negatively regulate cell cycle progression in the G1 phase. In this study, we investigated p130 expression in thyroid neoplasms. p130 overexpression was observed in 33.3% of follicular adenoma and 50% of follicular carcinoma and the incidences were not significantly different. In papillary carcinoma, it was overexpressed in 36.5% of cases, but in microcarcinoma, the incidence was significantly lower (14.3%). Furthermore, in anapalstic carcinoma, p130 overexpression was less frequently seen than in papillary carcinoma except for microcarcinoma and follicular carcinoma, and only 14.3% of cases overexpressed this protein. These findings suggest that: (1) reduced p130 expression may contribute to the aggressive character of anplastic carcinoma; and (2) p130 may specify the growth characteristics of microcarcinoma.


Asunto(s)
Diferenciación Celular , Fosfoproteínas/metabolismo , Proteínas , Neoplasias de la Tiroides/metabolismo , Neoplasias de la Tiroides/patología , Carcinoma/metabolismo , Carcinoma/patología , Carcinoma Papilar/metabolismo , Carcinoma Papilar/patología , División Celular , Humanos , Invasividad Neoplásica/patología , Proteína p130 Similar a la del Retinoblastoma
5.
Cancer Lett ; 200(2): 167-72, 2003 Oct 28.
Artículo en Inglés | MEDLINE | ID: mdl-14568171

RESUMEN

Previous studies have demonstrated that terminal fucosylation is associated with the biological aggressiveness of carcinomas, but the significance of core fucosylation (alpha1,6-fucosylation) through alpha1,6-fucosyltransferase (FUT8) has not been studied in depth. Herein, we investigated the expression of alpha1,6-fucosyltransferase (FUT8) in 133 cases of thyroid carcinomas using an immunohistochemical approach. The expression of FUT8 was quite low in normal follicules. A high expression of FUT8 was observed in 33.3% of papillary carcinoma and the incidence was directly linked to tumor size and lymph node metastasis. In contrast, this phenomenon was less frequently observed in follicular carcinoma and anaplastic (undifferentiated) carcinoma. These results suggest that FUT8 expression may be a key factor in the progression of thyroid papillary carcinomas, but not follicular carcinomas, and decreases in FUT8 expression might be linked to anaplastic transformation.


Asunto(s)
Carcinoma Papilar/enzimología , Carcinoma/enzimología , Fucosiltransferasas/metabolismo , Neoplasias de la Tiroides/enzimología , Carcinoma/patología , Carcinoma Papilar/patología , Diferenciación Celular , Humanos , Inmunohistoquímica , Invasividad Neoplásica , Metástasis de la Neoplasia , Neoplasias de la Tiroides/patología
7.
Oncol Rep ; 10(5): 1337-40, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-12883703

RESUMEN

Survivin is a novel member of the apoptosis protein inhibitors, but according to previous reports, it is also significantly linked to cell proliferating activity. In this study, we investigated the expression of survivin in thyroid neoplasms. Survivin was only occasionally expressed in normal follicular cells, whereas in follicular and papillary carcinomas, about 20% of cases were positive for survivin. The incidence was significantly higher in advanced stage papillary carcinoma (p=0.0080) and papillary and follicular carcinomas with poorly differentiated lesions (p=0.0150). In anaplastic carcinoma, survivin positivity was observed in 84% of the cases, which was in significantly higher incidence than in papillary or follicular carcinoma (p<0.0001). These results suggest that survivin is strongly related to the dedifferentiation of thyroid carcinoma.


Asunto(s)
Carcinoma/metabolismo , Proteínas Asociadas a Microtúbulos/biosíntesis , Neoplasias de la Tiroides/diagnóstico , Neoplasias de la Tiroides/metabolismo , Adenocarcinoma Folicular/diagnóstico , Adenocarcinoma Folicular/metabolismo , Adenocarcinoma Folicular/patología , Diferenciación Celular , División Celular , Transformación Celular Neoplásica , Humanos , Inmunohistoquímica , Proteínas Inhibidoras de la Apoptosis , Proteínas de Neoplasias , Survivin , Neoplasias de la Tiroides/patología
8.
Int J Mol Med ; 9(4): 373-6, 2002 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-11891530

RESUMEN

p57 (Kip2) belongs to the Cip/Kip family and is one of the universal negative regulators of the cell cycle. In this study, we investigated the p57 expression of various types of thyroid neoplasm. p57 overexpression was observed in only 4.2% of normal thyroid tissues. In follicular adenoma and minimally invasive follicular carcinoma, p57 was overexpressed in 100% and 91.7% of the cases, respectively. However, its incidence was significantly lower (p<0.0001) in widely invasive follicular carcinoma, of which only 36.4% overexpressed p57. This phenomenon was seen in 63.1% of papillary carcinoma and 13.3% of anaplastic (undifferentiated) carcinoma. Furthermore, poorly differentiated and undifferentiated carcinoma more frequently lacked p57 expression (p<0.0001). These results suggest that the down-regulation of p57 may play a role in the dedifferentiation of thyroid carcinoma and in follicular carcinoma mutating to be more invasive.


Asunto(s)
Proteínas Nucleares/biosíntesis , Glándula Tiroides/metabolismo , Neoplasias de la Tiroides/metabolismo , Diferenciación Celular , Inhibidor p57 de las Quinasas Dependientes de la Ciclina , Regulación hacia Abajo , Humanos , Inmunohistoquímica , Proteínas Nucleares/genética , Glándula Tiroides/patología , Neoplasias de la Tiroides/genética , Neoplasias de la Tiroides/patología
9.
Anticancer Res ; 23(1B): 569-76, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-12680148

RESUMEN

BACKGROUND: Apoptosis, programmed cell death, is one of the promnent factors in the evaluation of carcinoma characteristics. It is well-known that bcl-2 and its related proteins significantly modulate apoptosis. Bag-1 is a recently identified bcl-2-related protein and is known to be linked to the biological aggressiveness of some carcinomas. MATERIALS AND METHODS: We immunohistochemically investigated bag-1 and bcl-2 expression in various thyroid neoplasms using monoclonal antibodies. RESULTS: High bag-1 expression was observed in 66.7% of follicular adenoma and 75.0% of follicular carcinoma, and no statistical difference was established between them. In papillary carcinoma, 60.7% were classified with high bag-1 expression, whereas only 4.5% of anaplastic (undifferentiated) carcinoma highly expressed bag-1, and the incidence was significantly lower (p < 0.0001) than in papillary and follicular carcinomas. Furthermore, in thyroid neoplasm, bag-1 expression was directly linked (p < 0.0001) to bcl-2 expression. CONCLUSION: These findings suggest that bag-1 may interact with bcl-2 to play an important role in thyroid neoplasm before anaplastic transformation, and the disruption of events mediated by bag-1 and bcl-2 may be a typical characteristic of undifferentiated carcinoma.


Asunto(s)
Proteínas Portadoras/biosíntesis , Proteínas Proto-Oncogénicas c-bcl-2/biosíntesis , Neoplasias de la Tiroides/metabolismo , Neoplasias de la Tiroides/patología , Adenocarcinoma Folicular/metabolismo , Adenocarcinoma Folicular/patología , Carcinoma Papilar/metabolismo , Carcinoma Papilar/patología , Diferenciación Celular/fisiología , Proteínas de Unión al ADN , Humanos , Inmunohistoquímica , Factores de Transcripción
10.
Anticancer Res ; 23(3B): 2335-8, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-12894512

RESUMEN

BACKGROUND: Cyclin G2 is a novel cyclin negatively regulating the cell cycle progression, contrary to the characteristics of conventional cyclins. However, little is known about the cyclin G2 expression in human carcinomas. We thus investigated cyclin G2 expression in human thyroid neoplasms. MATERIALS AND METHODS: We immunohistochemically examined cyclin G2 expression in 40 normal thyroids and 80 thyroid neoplasms. RESULTS: Normal thyroids expressed cyclin G2 in more than 5% of follicular cells. Of 30 papillary carcinomas including 6 microcarcinoma, cyclin G2 expression was not, or only occasionally, observed in carcinoma cells, indicating its expression decreased in all these cases. On the other hand, in 16 of the 24 follicular adenomas (66.7%) and 5 of the 23 follicular carcinomas (21.7%), cyclin G2 expression was retained (more than 5% of neoplastic cells were positive), and adenomas more frequently (p = 0.0032) retained cyclin G2 expression than carcinomas. CONCLUSION: Our results suggest that lack of cyclin G2 plays an important role in the malignant transformation of papillary carcinoma. Also, it may play an adjuvant role in the transformation of follicular adenoma to carcinoma. This is the first study of the expression of cyclin G2, a novel cyclin having a role opposite to that of conventional cyclins, in human carcinoma.


Asunto(s)
Carcinoma Papilar/metabolismo , Transformación Celular Neoplásica/metabolismo , Ciclinas/biosíntesis , Neoplasias de la Tiroides/metabolismo , Carcinoma/metabolismo , Carcinoma/patología , Carcinoma Papilar/patología , Carcinoma Papilar Folicular/metabolismo , Carcinoma Papilar Folicular/patología , Ciclina G2 , Humanos , Neoplasias de la Tiroides/patología
11.
Pathol Res Pract ; 199(2): 79-83, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-12747469

RESUMEN

KAI1 is a metastasis suppressor gene located on human chromosome 11p11.2. Previous studies have shown that the down-regulation of KAI1 mRNA and decreased expression of its gene product are significantly linked to carcinoma progression, including metastatic ability. In this study, we investigated KAI1 protein expression in thyroid neoplasms. KAI1 overexpression was observed in 64.0% of papillary carcinoma cases, and the incidence was significantly higher than in cases of follicular carcinoma (20.0%) (p = 0.0001). In papillary carcinomas, decreased KAI1 expression was frequently observed in cases invading beyond the thyroid capsule (p = 0.001), as well as in lymph node metastases (p = 0.0047) and poorly differentiated lesions (p = 0.0299). Furthermore, in anaplastic carcinoma, the incidence of KAI1 overexpression was lower than in papillary carcinoma (p < 0.0001), and only 4.2% of the cases overexpressed this gene. These results suggest that KAI1 down-regulation is significantly related to the progression of papillary carcinoma, including lymph node metastasis, and its anaplastic transformation.


Asunto(s)
Antígenos CD , Biomarcadores de Tumor/análisis , Genes Supresores de Tumor , Glicoproteínas de Membrana/biosíntesis , Proteínas Proto-Oncogénicas , Neoplasias de la Tiroides/metabolismo , Neoplasias de la Tiroides/patología , Adenocarcinoma Folicular/metabolismo , Adenocarcinoma Folicular/patología , Carcinoma/metabolismo , Carcinoma/patología , Carcinoma Papilar/metabolismo , Carcinoma Papilar/patología , Regulación hacia Abajo , Regulación Neoplásica de la Expresión Génica , Humanos , Inmunohistoquímica , Proteína Kangai-1 , Metástasis Linfática/patología , Invasividad Neoplásica/patología
12.
Pathol Res Pract ; 198(6): 397-402, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12166896

RESUMEN

Previous studies have demonstrated that cell proliferating activity accurately reflects the biological aggressiveness of thyroid neoplasms. In this study, we focused on the G2-M boundary regulators of the cell cycle and investigated the expression of three proteins, cyclin A, cyclin B1 and cdc2. The incidence of cyclin A overexpression was significantly linked to carcinoma differentiation (p < 0.0001) and, in particular, all 21 cases of undifferentiated carcinoma overexpressed this protein. On the other hand, cyclin B1 was overexpressed in four undifferentiated carcinomas (19.0%), but not in carcinomas of other types. Cdc2 overexpression was also related to carcinoma differentiation (p < 0.0001), and was directly linked to cyclin A overexpression (p < 0.0001), but not to cyclin B1 overexpression. No significant relationship could be established between the overexpression of these proteins and the histological type of follicular tumor. These results suggest that cyclin A, rather than cyclin B1, contributes significantly to the aggressive character of thyroid carcinoma, together with cdc2.


Asunto(s)
Adenoma/metabolismo , Proteína Quinasa CDC2/biosíntesis , Carcinoma/metabolismo , Ciclina A/biosíntesis , Ciclina B/biosíntesis , Neoplasias de la Tiroides/metabolismo , Adenoma/patología , Carcinoma/patología , División Celular , Ciclina B1 , Humanos , Técnicas para Inmunoenzimas , Antígeno Ki-67/metabolismo , Neoplasias de la Tiroides/patología
13.
Nihon Geka Gakkai Zasshi ; 104(6): 488-90, 2003 Jun.
Artículo en Japonés | MEDLINE | ID: mdl-12854498

RESUMEN

Detection of thyroglobulin, CEA, and calcitonin in serum and tissue is very useful to make differential diagnosis among papillary, follicular, and medullary carcinoma of the thyroid. The case was a 70-year-old woman with a nodule of the thyroid, presenting elevated serum level of thyroglobulin and CEA (22.0 ng/ml). Both serum level of thyroglobulin and CEA decreased after surgery. One year and nine months after surgery, she died from systemic metastases of thyroid carcinoma. Histological examination of the tumor presented to be poorly differentiated type of follicular carcinoma, presenting positive of both thyroglobulin and CEA, and negative of calcitonin in the cytoimmunochemistry. This case was identified to be a rare case that tumor cells of poorly differentiated follicular carcinoma produced and secreted both thyroglobulin and CEA.


Asunto(s)
Adenocarcinoma Folicular/diagnóstico , Biomarcadores de Tumor/sangre , Antígeno Carcinoembrionario/sangre , Tiroglobulina/sangre , Neoplasias de la Tiroides/diagnóstico , Adenocarcinoma Folicular/fisiopatología , Adenocarcinoma Folicular/cirugía , Anciano , Antígeno Carcinoembrionario/biosíntesis , Femenino , Humanos , Neoplasias de la Tiroides/fisiopatología , Neoplasias de la Tiroides/cirugía
15.
Surg Today ; 34(11): 891-5, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15526121

RESUMEN

PURPOSE: To investigate the factors associated with a favorable prognosis after reoperation for local recurrent papillary thyroid carcinoma (PTC), we reviewed 45 patients who underwent surgery for first local recurrence of PTC. METHODS: We divided the patients into two groups. Group A (n = 28) had no second recurrence, and group B (n = 17) had second local recurrence after surgery for recurrence. RESULTS: The mean follow-up period after reoperation was 56.9 months. The mean age at the time of reoperation in group A was significantly lower than that in group B, at 48.1 years versus 62.3 years, respectively (P = 0.0007). The mean age at the time of the initial operation in group A was also significantly lower than that in group B, at 40.1 years versus 55.1 years, respectively (P = 0.0006). Patients with recurrent tumors only outside the area dissected at the initial operation (n = 27) had a better outcome than those with recurrence within the dissected area (n = 18; P = 0.0127). Patients who underwent systematic partial or modified neck dissection (n = 36) had a better outcome than those who underwent only simple local resection (n = 9; P = 0.0169). CONCLUSION: For local recurrent PTC, systematic neck dissection is recommended over local resection of recurrent tumors.


Asunto(s)
Carcinoma Papilar/cirugía , Recurrencia Local de Neoplasia/cirugía , Neoplasias de la Tiroides/cirugía , Adulto , Anciano , Carcinoma Papilar/mortalidad , Carcinoma Papilar/patología , Estudios de Cohortes , Femenino , Humanos , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/mortalidad , Recurrencia Local de Neoplasia/patología , Estadificación de Neoplasias , Probabilidad , Pronóstico , Reoperación , Medición de Riesgo , Tasa de Supervivencia , Neoplasias de la Tiroides/mortalidad , Neoplasias de la Tiroides/patología , Resultado del Tratamiento
16.
Oncology ; 64(1): 83-9, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-12457035

RESUMEN

OBJECTIVE: Counterattack by RCAS1 on carcinoma to cytotoxic T cells and natural killer (NK) cells has been suggested as a contribution to carcinoma progression, because RCAS1 can inhibit their proliferation and induce apoptosis. In this study, we examined RCAS1 expression in various thyroid neoplasms in order to clarify its clinical significance. METHODS: We studied RCAS1 expression by means of immunohistochemistry using a mouse monoclonal antibody against RCAS1 for normal thyroid epithelium, follicular adenoma, follicular carcinoma, papillary carcinoma and undifferentiated (anaplastic) carcinoma. RESULTS: Normal epithelium and follicular adenoma did not express or only faintly expressed RCAS1. In thyroid carcinomas. RCAS1 overexpression was more frequently observed in anaplastic (undifferentiated) carcinomas than papillary (p < 0.0001) and follicular carcinomas (p = 0.0018). In follicular carcinoma, the widely invasive type more frequently overexpressed RCAS1 than the minimally invasive type (p = 0.0488). Furthermore, the incidences of RCAS1 overexpression increased with carcinoma dedifferentiation (p < 0.0001). CONCLUSION: These results suggest that RCAS1 may contribute to the progression of thyroid carcinoma with high biological aggressiveness.


Asunto(s)
Antígenos de Neoplasias/metabolismo , Biomarcadores de Tumor/metabolismo , Neoplasias de la Tiroides/metabolismo , Adenocarcinoma Folicular/metabolismo , Adenocarcinoma Folicular/patología , Adenoma/metabolismo , Adenoma/patología , Carcinoma/metabolismo , Carcinoma/patología , Carcinoma Papilar/metabolismo , Carcinoma Papilar/patología , Estudios de Casos y Controles , Diferenciación Celular , Humanos , Técnicas para Inmunoenzimas , Antígeno Ki-67/metabolismo , Glándula Tiroides/metabolismo , Neoplasias de la Tiroides/patología , Regulación hacia Arriba
17.
Surg Today ; 33(4): 277-81, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-12707822

RESUMEN

We herein report a case of anaplastic thyroid carcinoma in a 77-year-old woman with long-term disease-free survival. The tumor measured 7.5 x 6.0 cm in size and was diagnosed to be anaplastic carcinoma. We investigated the biological aggressiveness of this carcinoma by means of immunohistochemistry and found it have a high cell-proliferating activity, a disruption in the mechanism of apoptosis, and a high potential of cell spreading, similar to that observed in usual anaplastic carcinomas. The only unique point was that this tumor was encapsulated and no invasion of carcinoma cells beyond the capsule was microscopically observed. To avoid an obstruction of the trachea, a lobectomy without lymph node dissection was performed as a "palliative operation." Although neither adjuvant chemotherapy nor radiotherapy was carried out due to her age, she has nevertheless survived with no evidence of recurrence for 57 months after surgery. The presence of such a type of anaplastic carcinoma should thus be noted by surgeons and pathologists, even though the occurrence of such cases seems to be very rare.


Asunto(s)
Neoplasias de la Tiroides/metabolismo , Anciano , Anaplasia/metabolismo , Femenino , Humanos , Inmunohistoquímica , Invasividad Neoplásica , Pronóstico , Neoplasias de la Tiroides/patología , Neoplasias de la Tiroides/cirugía , Tiroidectomía
18.
Endocr J ; 50(5): 595-601, 2003 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-14614216

RESUMEN

TSH receptor antibodies (TRAb) are generally regarded as mediators of thyroid stimulation in Graves' disease. In addition, a high serum TRAb value during pregnancy is one of the risk factors for intrauterine death, prematurity, and fetal or neonatal hyperthyroidism. Recently, correlations between a high serum TRAb value and endocrine opthalmopathy were also suggested. Surgical resection of the thyroid is usually followed by a reduction of serum TRAb levels in variable degrees. The relation between the extent of the thyroidectomy and the degree of reduction is still controversial. In addition, the changes in the TRAb value after total thyroidectomy (TT) over a long period of time have never been studied. We studied the changes in serum TRAb values after TT and subtotal thyroidectomy (ST) for more than 7 years. Forty-one patients with Graves' disease underwent TT, and 99 patients underwent ST. The serum TRAb values and the ratio of the patients who achieved normal values among each group (normalization rates of TRAb) at 3 and 6 months, 1, 3, 5 and 7 years after surgery were compared between the TT group and ST group. The mean preoperative TRAb values were not significantly different between the TT and ST groups, and the mean TRAb values measured 3, 6 and 12 months after surgery were not significantly different between the groups. However, the TRAb values measured 3, 5 and 7 years after surgery were significantly (p<0.05) lower in the TT group than in the ST group (16.7 +/- 3.3% vs 28.0 +/- 2.6%, 12.6 +/- 3.4% vs 29.3 +/- 3.8%, 5.6 +/- 0.9% vs 25.4 +/- 4.1%, respectively). The normalization rates of TRAb were not significantly different between the groups until 1 year after surgery. However, the normalization rates 3, 5 and 7 years after surgery were significantly (p<0.05) higher in the TT group than in the ST group (65.7% vs 42.4%, 77.3% vs 46.7%, 100% vs 59.1%, respectively). The surgical complication rates of TT were similar to ST except for permanent hypoparathyroidism. TT is a treatment option for Graves' disease, especially in patients with a high TRAb value who wish to have children or who have Graves' opthalmopathy.


Asunto(s)
Autoanticuerpos/sangre , Enfermedad de Graves/sangre , Enfermedad de Graves/cirugía , Receptores de Tirotropina/sangre , Tiroidectomía , Adolescente , Adulto , Anciano , Femenino , Humanos , Hipoparatiroidismo/etiología , Inmunoglobulinas Estimulantes de la Tiroides , Masculino , Persona de Mediana Edad , Periodo Posoperatorio , Tiroidectomía/efectos adversos , Tiroidectomía/métodos
19.
World J Surg ; 26(8): 1023-8, 2002 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-12016484

RESUMEN

Although sporadic medullary thyroid carcinoma (MTC) tends to be unicentric and confined to one lobe, total thyroidectomy is usually performed because of the risk of a hereditary or bilateral process. Germline RET mutation analysis can discriminate hereditary MTC and truly sporadic, nonhereditary MTC. We analyzed 72 of 94 patients with MTC to establish the genetic nature and the clinical features of nonhereditary MTC. Since 1996 we have prospectively treated 15 patients with nonhereditary MTC (prospective study group, or PSG) according to a unilateral surgery policy. A group of 22 previously operated patients in whom the nonhereditary nature was established served as controls (retrospective study group, or RSG). Systematic central and ipsilateral neck dissection was performed in both groups. Outcome was assessed using postoperative stimulated serum calcitonin levels; a normal value was considered a biochemical cure. All 24 hereditary MTC patients carried germline RET mutations: 8 of 48 patients with apparently sporadic MTC had the mutations, and 6 of the 8 had bilateral MTC. All 40 patients without mutations had a unilateral tumor. In the RSG group 15 of 22 (68%) patients underwent total thyroidectomy, and the biochemical cure rate was 68%. Although only 3 of 15 (20%) of the PSG patients underwent total thyroidectomy, 12 of the 15 (80%) achieved biochemical cure. Univariate analyses revealed that pathologic node involvement- high T and N stages-was adversely related to biochemical cure. The extent of thyroid resection was not related to biochemical cure. Of 20 patients with node involvement, 10 achieved biochemical cure, indicating the importance of systematic neck dissection. Hemithyroidectomy with systematic central and ipsilateral neck dissection is appropriate surgery for nonhereditary MTC.


Asunto(s)
Carcinoma Medular/cirugía , Proteínas de Drosophila , Mutación de Línea Germinal , Proteínas Proto-Oncogénicas/genética , Proteínas Tirosina Quinasas Receptoras/genética , Neoplasias de la Tiroides/cirugía , Tiroidectomía/métodos , Adulto , Anciano , Carcinoma Medular/genética , Análisis Mutacional de ADN , Femenino , Humanos , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia , Estudios Prospectivos , Proteínas Proto-Oncogénicas/análisis , Proteínas Proto-Oncogénicas c-ret , Proteínas Tirosina Quinasas Receptoras/análisis , Neoplasias de la Tiroides/genética
20.
Pathol Int ; 53(7): 429-33, 2003 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-12828607

RESUMEN

Recent studies have demonstrated that Y-box binding protein (YB-1) regulates the transcription of genes linked to carcinoma progression. In this study, we investigated the expression of this protein in thyroid neoplasms to elucidate its significance. The expression of YB-1 was immunohistochemically investigated using the monoclonal antibody for various thyroid neoplasms. Normal follicles did not overexpress YB-1, and only moderate overexpression of YB-1 was observed in some follicular tumors and papillary carcinoma, especially those of a larger size. In contrast, 92.9% of anaplastic carcinoma strongly overexpressed YB-1. YB-1 immunoreactivity was seen in both cytoplasms and cell nuclei, but the former was more predominant. These findings suggest that YB-1 plays a role in regulating the transcription as well as translation of genes contributing to the anaplastic transformation of thyroid carcinoma.


Asunto(s)
Proteínas Potenciadoras de Unión a CCAAT/metabolismo , Carcinoma/metabolismo , Transformación Celular Neoplásica/metabolismo , Proteínas de Unión al ADN , Neoplasias de la Tiroides/metabolismo , Factores de Transcripción/metabolismo , Adenocarcinoma Folicular/metabolismo , Adenocarcinoma Folicular/patología , Adenocarcinoma Papilar/metabolismo , Adenocarcinoma Papilar/patología , Carcinoma/patología , Transformación Celular Neoplásica/patología , Humanos , Técnicas para Inmunoenzimas , Antígeno Ki-67/metabolismo , Factores de Transcripción NFI , Proteínas Nucleares , Glándula Tiroides/metabolismo , Neoplasias de la Tiroides/patología , Proteína 1 de Unión a la Caja Y
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA